Altura Medical is a venture‑backed medical device company that developed an ultra‑low‑profile endovascular stent graft system for treatment of abdominal aortic aneurysms (AAAs) and related aortic disease; the business was founded in 2008 and was acquired by Lombard Medical (Lombard Medical Technologies) following CE mark and international commercialization activity in 2015–2016[3][4].
High‑Level Overview
- Concise summary: Altura Medical built a next‑generation endograft (stent‑graft) platform intended to simplify endovascular aneurysm repair (EVAR) by using an ultra‑low‑profile delivery system and a positional, modular graft design that allowed repositioning during deployment and avoided complex cannulation steps[3][4]. The company served vascular surgeons and hospitals treating AAAs and thoracic aortic disease, positioning its device as a way to reduce procedure complexity and potentially shorten procedure times and recovery versus open repair[3][4].
- For a portfolio‑company style assessment:
- Product: an ultra‑low‑profile endovascular stent graft (endograft) system for EVAR procedures[3][4].
- Customers: vascular surgeons, interventionalists, and hospitals/ASCs performing EVAR[3].
- Problem solved: reduces device profile and deployment complexity (repositionable graft placement, no need for cannulation), aiming to make EVAR more predictable, faster, and accessible for standard AAA anatomies[4].
- Growth momentum: Altura obtained CE Mark in 2015, attracted venture funding (reported total raise ~$39.5M) and was acquired by Lombard Medical in 2015 with planned European launches and US clinical study filings under Lombard’s stewardship[3][4].
Origin Story
- Founding year and exit: Altura Medical was founded in 2008 and later acquired by Lombard Medical in an agreement announced in August 2015; the deal included upfront and milestone payments and aimed to accelerate international commercial rollout after the CE Mark[3][4].
- Founders / background & idea emergence: public profiles cite Altura as a Silicon‑Valley–based, venture‑backed medical device startup focused on an innovative ultra‑low‑profile stent graft; specific founder names are not prominent in the cited sources, but the company’s technical differentiation centered on reducing delivery system size while maintaining graft robustness and enabling accurate positioning during deployment[3][4].
- Early traction / pivotal moments: the device received CE Mark in 2015, Lombard announced plans for European launch (early 2016) and to pursue a US IDE and clinical study, and the acquisition by Lombard was framed as validation of the technology and commercial potential[4][3].
Core Differentiators
- Ultra‑low‑profile delivery: designed to reduce access vessel requirements and facilitate use in patients with smaller or diseased iliac/femoral arteries compared with larger systems[4].
- Repositionable, modular deployment: the system permitted repositioning during deployment and placement of each graft relative to renal arteries without the need for cannulation, improving procedural predictability[4].
- Shorter, simpler procedures: the intended outcome was simpler, more intuitive deployment with potentially shorter procedure times and consistent results—important in high‑volume vascular practice[4].
- Clinical and regulatory progress: CE Mark approval and subsequent acquisition by Lombard provided regulatory and commercialization validation points for the technology[4][3].
Role in the Broader Tech/MedDev Landscape
- Trend alignment: Altura rode the larger trend toward minimally invasive endovascular therapies replacing open vascular surgery, driven by aging populations, higher AAA detection, and demand for faster recovery and lower perioperative morbidity[3][4].
- Timing: innovations that lower device profile and simplify deployment are especially valuable as clinicians treat older patients with smaller access vessels or complex anatomies, increasing the addressable population for EVAR[4].
- Market forces: rising adoption of EVAR over open repair, demand for devices that handle varied anatomies, and continued international regulatory pathways (CE mark, then US IDE) created commercial opportunity[3][4].
- Ecosystem influence: by emphasizing deployment simplicity and low profile, Altura’s design goals pushed competitors and acquirers (e.g., Lombard) to expand their product portfolios to address access‑site limitations and procedural efficiency in EVAR[4].
Quick Take & Future Outlook
- What’s next (post‑acquisition context): after acquisition, the logical next steps were European commercialization (planned launch in 2016) and pursuing US IDE/clinical trials under Lombard to secure FDA clearance and broader market access[4]. The acquisition signaled consolidation in EVAR device providers where novel delivery and graft concepts are brought into larger commercial platforms[4][3].
- Trends that will shape trajectory: continued emphasis on lower‑profile systems, enhanced sealing/fixation for challenging anatomies, branched/fenestrated solutions for complex necks, and outcomes data demonstrating durability and reintervention rates will determine long‑term uptake and competitive positioning in the EVAR market[3][4].
- How influence might evolve: if the Altura design translated into favorable clinical outcomes and commercial uptake under Lombard, its technology could become a standard option for specific patient anatomies and influence future stent‑graft engineering toward modular, repositionable, and low‑profile systems[4][3].
Quick factual anchors: Altura Medical — founded 2008; focused on ultra‑low‑profile endograft for AAA/EVAR; CE Mark in 2015 and acquired by Lombard Medical in 2015 with planned European launch and US IDE activity reported[3][4].
If you’d like, I can:
- Pull and summarize peer‑reviewed clinical outcomes or registries for the Altura endograft (if available).
- Create a one‑page investor brief comparing Altura’s technical specs to contemporary EVAR devices.
